Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients

Psychiatric Services

Volumn 55, Issue 9, 2004, Pages 1006-1013

  Citrome, Leslie ^a,b   Jaffe, Ari ^a,b   Levine, Jerome ^a,b   Allingham, Baerbel ^a   Robinson, James ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ANTIDIABETIC AGENT; ARIPIPRAZOLE; CHLORPROPAMIDE; CLOZAPINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; LOXAPINE; MESORIDAZINE; METFORMIN; MIGLITOL; MOLINDONE; NATEGLINIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIOGLITAZONE; QUETIAPINE; REPAGLINIDE; RISPERIDONE; ROSIGLITAZONE; THIORIDAZINE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG; ZIPRASIDONE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; DIABETES MELLITUS; FEMALE; GENDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; RISK ASSESSMENT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CLOZAPINE; DEMOGRAPHY; DIABETES MELLITUS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS;

EID: 4444286682     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.55.9.1006     Document Type: Article

References (37)

1. Koller E, Schneider B, Bennett K, et al: Clozapine-associated diabetes. American Journal of Medicine 111:716-723, 2001
2. Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852, 2002
3. Koller EA, Cross JT, Doraiswamy PM, et al: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23:735-744, 2003
4. Koller EA, Weber J, Doraiswamy PM, et al: A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Journal of Clinical Psychiatry 65:857-863, 2004
5. Lund BC, Perry PJ, Brooks JM, et al: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Archives of General Psychiatry 58:1172-1176, 2001
6. Sernyak MJ, Leslie DL, Alarcon RD, et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry 159:561-566, 2002
7. Wang PS, Glynn RJ, Ganz DA, et al: Clozapine use and risk of diabetes mellitus. Journal of Clinical Psychopharmacology 22: 236-243, 2002
8. Koro CE, Fedder DO, L'Italien GJ, et al: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. British Medical Journal 325:243-247, 2002
9. Kornegay CJ, Vasilakis-Scaramozza C, Jick H: Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. Journal of Clinical Psychiatry 63:758-762, 2002
10. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Journal of Clinical Psychiatry 63:920-930, 2002
11. Caro J, Ward A, Levinton C, et al: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Journal of Clinical Psychiatry 63:1135-1139, 2002
12. Buse JB, Cavazzoni P, Hornbuckle K, et al: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology 56:164-170, 2003
13. Gianfrancesco F, Grogg A, Mahmoud R, et al: Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clinical Therapeutics 25:1150-1171, 2003
14. Gianfrancesco F, White R, Wang RH, et al: Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. Journal of Clinical Psychopharmacology 23:328-335, 2003
15. Fuller MA, Shermock KM, Secic M, et al: Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23:1037-1043, 2003
16. Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biological Psychiatry 4:778-783, 1998
17. Melkersson KI, Hulting AL: Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 154:205-212, 2001
18. Citrome L, Jaffe A: Relationship of atypical antipsychotics with development of diabetes mellitus. Annals of Pharmacotherapy 37:1849-1857, 2003
19. Citrome L, Levine J, Allingham B: Utilization of depot neuroleptic medication in psychiatric inpatients, Psychopharmacology Bulletin 32:321-326, 1996
20. Levine J, Citrome L, Allingham B: An effectiveness study comparing oral and depot neuroleptic medications. Psychopharmacology Bulletin 33:476, 1997
21. Jaffe AB, Levine J: Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and Drug Safety 12:41-48, 2003
22. Levine J, Jaffe AB: Antipsychotic Medication Utilization in a State Mental Hospital System, 1994-2000, in Mental Health, United States, 2002. Edited by Manderscheid RW, Henderson MJ. Department of Health and Human Services pub no SMA-3938. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2004
23. Javitt DC, Cienfuegos A, Miniati M, et al: A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. Journal of Clinical Psychiatry 63:585-590, 2002
24. Citrome L, Levine J, Allingham B: Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatric Quarterly 69:283-300, 1998
25. Citrome L, Levine J, Allingham B: Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51:634-638, 2000
26. Citrome L, Jaffe A, Levine J: Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatric Services 53:1212, 2002
27. SPSS Advanced Models 10.0. Chicago, Ill, Prentice Hall, 1999
28. Braithwaite W, Cole P, Feinstein AR, et al: The Role of Epidemiology in Decision-Making. Annapolis Center, 1999. Available at www.annapoliscenter.org
29. Dixon L, Weiden P, Delahanty J, et al: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26:903-912, 2000
30. Sobel M, Jaggers ED, Franz MA: New-on-set diabetes mellitus associated with the initiation of quetiapine treatment. Journal of Clinical Psychiatry 60:556-557, 1999
31. Procyshyn RM, Pande S, Tse G: New-onset diabetes mellitus associated with quietapine. Canadian Journal of Psychiatry 45:668-669, 2000
32. Domon SE, Cargile CS: Quetiapine-associated hyperglycemia and hypertriglyceridemia. Journal of the American Academy of Child and Adolescent Psychiatry 41:495-496, 2002
33. Lambert BL, Chou CH, Chang KY, et al: Antipsychotic use and new onset type II diabetes among schizophrenics. Schizophrenia Research 60(suppl 1):359-360, 2003
34. Cunningham F, Lambert B, Miller DR, et al: Antipsychotic induced diabetes in Veteran schizophrenic patients. Pharmacoepidemiology and Drug Safety 12(suppl 1):S154-S155, 2003
35. Mokdad AH, Ford ES, Bowman BA, et al: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79, 2003
36. Taylor DM, McAskill R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavica 101:416-432, 2000
37. Citrome L: The increase in risk of diabetes mellitus from exposure to second generation antipsychotics. Drugs of Today 40: 445-464, 2004